Stockscreener 앱 받기
0.8998
3.25%
-0.0302
Clearside Biomedical Inc 주식(CLSD)의 최신 뉴스
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Key Strategic Updates Expected: Clearside Biomedical CEO Takes Stage at Major Healthcare Conference - Stock Titan
Clearside Biomedical’s (CLSD) Buy Rating Reaffirmed at HC Wainwright - Defense World
Clearside Biomedical’s SWOT analysis: wet AMD stock eyes flexible dosing edge - Investing.com Australia
Clearside Biomedical’s SWOT analysis: wet AMD stock eyes flexible dosing edge By Investing.com - Investing.com South Africa
Clearside outlines pivotal Phase 3 plans for CLS-AX in wet AMD - MSN
Clearside Biomedical (NASDAQ:CLSD) Earns “Buy” Rating from Chardan Capital - Defense World
Needham & Company LLC Has Lowered Expectations for Clearside Biomedical (NASDAQ:CLSD) Stock Price - Defense World
Clearside Biomedical Full Year 2024 Earnings: In Line With Expectations - Yahoo Finance
JMP reiterates Clearside Biomedical stock with $5 target By Investing.com - Investing.com Canada
Clearside Biomedical’s Positive Earnings Call Highlights Progress and Challenges - TipRanks
Stifel maintains Clearside Biomedical buy rating, $8 target By Investing.com - Investing.com UK
Clearside Biomedical (CLSD) Prepares for Phase 3 Trials, Seeks F - GuruFocus
Clearside Biomedical Reports Net Loss for Fourth Quarter and Full Year 2024 - VisionMonday.com
Clearside Biomedical Reports 2024 Earnings and Strategic Progress - TipRanks
Earnings call transcript: Clearside Biomedical Q4 2024 revenue beats forecast By Investing.com - Investing.com South Africa
Earnings call transcript: Clearside Biomedical Q4 2024 revenue beats forecast - Investing.com India
Clearside Biomedical Inc (CLSD) Q4 2024 Earnings: EPS Matches Es - GuruFocus
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Clearside Biomedical Reports 2024 Financial Results and Updates - TipRanks
Clearside Biomedical Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Clearside Biomedical earnings matched, revenue topped estimates - Investing.com
CLEARSIDE BIOMEDICAL Earnings Results: $CLSD Reports Quarterly Earnings - Nasdaq
Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Clearside Reports 95% Revenue Decline, But Secures Critical FDA Agreement for Phase 3 Trial - Stock Titan
Exploring Clearside Biomedical's Earnings Expectations - Benzinga
Clearside Biomedical Announces Six Abstracts Accepted for - GlobeNewswire
Game-Changing Eye Treatment Data: Clearside to Present Phase 2b Results at ARVO 2025 - Stock Titan
Clearside Biomedical Presents Comparative Data on CLS-AX for Wet AMD at 2025 Wet AMD & Diabetic Eye Disease Summit - Nasdaq
Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet - GlobeNewswire
Clearside's Revolutionary Eye Treatment Platform Targets $12B Wet AMD Market After FDA Green Light - StockTitan
Clearside Biomedical (NASDAQ:CLSD) Downgraded to Sell Rating by StockNews.com - Defense World
Clearside Biomedical to Report Fourth Quarter and Full Year - GlobeNewswire
Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025 - The Manila Times
Clearside Biomedical, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025 - Nasdaq
Clearside Biomedical Q4 Earnings: Key Date Announced for Critical Year-End Financial Results - StockTitan
Clearside Biomedical (CLSD) Projected to Post Earnings on Tuesday - Defense World
HC Wainwright Reiterates “Buy” Rating for Clearside Biomedical (NASDAQ:CLSD) - Defense World
Clearside Biomedical, Inc. to Host Earnings Call - ACCESS Newswire
Clearside Biomedical Announces Successful End-of-Phase 2 - GlobeNewswire
Buy Rating on Clearside Biomedical: Strategic Advancements in CLS-AX Program for wAMD - TipRanks
Promising Potential of Clearside Biomedical’s CLS-AX Treatment Justifies Buy Rating - TipRanks
Clearside Biomedical (CLSD) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Clearside Biomedical announces successful End-of-Phase 2 meeting for CLS-AX - TipRanks
Can This New Wet AMD Treatment Challenge the $12B Market? FDA Says Yes to Phase 3 - StockTitan
Clearside Biomedical stock hits 52-week low at $0.79 - Investing.com
Clearside Biomedical Inc. Revolutionizes Panuveitis Treatment With Innovative Xipere Product: Key Trend in ... - WhaTech
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of “Buy” by Brokerages - Defense World
Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Buys $13,800.00 in Stock - MarketBeat
Clearside Biomedical director Thorp Clay buys $13,800 in stock By Investing.com - Investing.com South Africa
Clearside Biomedical director Thorp Clay buys $13,800 in stock - Investing.com India
Director Makes Bold Move with New Stock Purchase in Clearside Biomedical - TipRanks
1.23%
1.63%
자본화:
|
볼륨(24시간):